MENU
CLOV
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CLOV stock forecast, quote, news & analysis

Clover Health Investments Corp is a healthcare technology company... Show more

A.I.Advisor
published price charts
A.I.Advisor
a Summary for CLOV with price predictions
Nov 10, 2026

CLOV's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CLOV turned positive on November 09, 2026. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 56 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLOV as a result. In 58 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

CLOV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 225 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

CLOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.804) is slightly higher than the industry average of (3.520). P/E Ratio (-120.500) is within average values for comparable stocks, (126.353). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. CLOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was 1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 17%. PGNY experienced the highest price growth at 25%, while CVS experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was -34% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 41
Price Growth Rating: 42
SMR Rating: 72
Profit Risk Rating: 82
Seasonality Score: -1 (-100 ... +100)
CLOV's MACD Histogram crosses above signal line